Lungs & airways
Do you have a diagnosis of idiopathic pulmonary fibrosis (IPF)? If so, we would like you to comment on a Cochrane protocol - 'Anti-fibrotic therapies for idiopathic pulmonary fibrosis'
Skills: Consumer Input, Peer Review - Consumer
Anti-fibrotic therapies for idiopathic pulmonary fibrosis
Idiopathic pulmonary fibrosis (IPF) is a condition in which the lungs become scarred and breathing becomes increasingly difficult. It's not clear what causes it, but it usually affects adults who are around 70 to 75 years old, and is rare in the under 50s. Several treatments can help reduce the rate at which IPF gets worse, but there's currently no treatment that can stop or reverse the scarring of the lungs. Symptoms can include: shortness of breath, a persistent dry cough tiredness, loss of appetite and weight loss and rounded and swollen fingertips (clubbed fingers). Anti-fibrotic medicines (pirfenidone and nintedanib) work by reducing the rate at which scarring worsens.
The purpose of this review is to summarise the available published data regarding the efficacy and safety of pirfenidone and nintedanib in those adults with IPF.
We are looking for adults who have a diagnosis of IPF or someone who cares for an adult with a diagnosis of IPF.